Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Defining criteria for disease activity states in juvenile dermatomyositis based on the Juvenile Dermatomyositis Activity Index

S. Rosina, A. Consolaro, A. Pistorio, A. Rebollo-Giménez, C. Bracaglia, P. Dolezalova, A. Guilaisne Bernard-Medina, T. Herlin, M. Trachana, V. Vargová, C. Wouters, L. Carenini, N. Ruperto, A. Ravelli, Paediatric Rheumatology International Trials...

. 2024 ; 10 (1) : . [pub] 20240202

Language English Country England, Great Britain

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc24007214

OBJECTIVES: To develop and validate the cut-offs in the Juvenile DermatoMyositis Activity Index (JDMAI) to distinguish the states of inactive disease (ID), low disease activity (LDA), moderate disease activity (MDA) and high disease activity (HDA) in children with juvenile dermatomyositis (JDM). METHODS: For cut-off definition, data from 139 patients included in a randomised clinical trial were used. Among the six versions of the JDMAI, JDMA1 (score range 0-40) and JDMAI2 (score range 0-39) were selected. Optimal cut-offs were determined against external criteria by calculating different percentiles of score distribution and through receiver operating characteristic curve analysis. External criteria included the modified Pediatric Rheumatology International Trials Organization (PRINTO) criteria for clinically ID in JDM (for ID) and PRINTO levels of improvement in the clinical trial (for LDA and HDA). MDA cut-offs were set at the score interval between LDA and HDA cut-offs. Cut-off validation was conducted by assessing construct and discriminative ability in two cohorts including a total of 488 JDM patients. RESULTS: The calculated JDMAI1 cut-offs were ≤2.4 for ID, ≤6.6 for LDA, 6.7-11 for MDA and >11 for HDA. The calculated JDMAI2 cut-offs were ≤5.2 for ID, ≤8.5 for LDA, 8.6-11.3 for MDA and >11.3 for HDA. The cut-offs discriminated strongly among disease activity states defined subjectively by caring physicians and parents, parents' satisfaction or non-satisfaction with illness outcome, levels of pain, fatigue, physical functional impairment and physical well-being. CONCLUSIONS: Both JDMAI1 and JDMAI2 cut-offs revealed good metrologic properties in validation analyses and are, therefore, suited for application in clinical practice and research.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24007214
003      
CZ-PrNML
005      
20240423155810.0
007      
ta
008      
240412s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1136/rmdopen-2023-003093 $2 doi
035    __
$a (PubMed)38307698
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Rosina, Silvia $u UOC Reumatologia e Malattie Autoinfiammatorie, IRCCS Istituto Giannina Gaslini, Genova, Italy silviarosina@gaslini.org $1 https://orcid.org/0000000236676155
245    10
$a Defining criteria for disease activity states in juvenile dermatomyositis based on the Juvenile Dermatomyositis Activity Index / $c S. Rosina, A. Consolaro, A. Pistorio, A. Rebollo-Giménez, C. Bracaglia, P. Dolezalova, A. Guilaisne Bernard-Medina, T. Herlin, M. Trachana, V. Vargová, C. Wouters, L. Carenini, N. Ruperto, A. Ravelli, Paediatric Rheumatology International Trials Organisation (PRINTO)
520    9_
$a OBJECTIVES: To develop and validate the cut-offs in the Juvenile DermatoMyositis Activity Index (JDMAI) to distinguish the states of inactive disease (ID), low disease activity (LDA), moderate disease activity (MDA) and high disease activity (HDA) in children with juvenile dermatomyositis (JDM). METHODS: For cut-off definition, data from 139 patients included in a randomised clinical trial were used. Among the six versions of the JDMAI, JDMA1 (score range 0-40) and JDMAI2 (score range 0-39) were selected. Optimal cut-offs were determined against external criteria by calculating different percentiles of score distribution and through receiver operating characteristic curve analysis. External criteria included the modified Pediatric Rheumatology International Trials Organization (PRINTO) criteria for clinically ID in JDM (for ID) and PRINTO levels of improvement in the clinical trial (for LDA and HDA). MDA cut-offs were set at the score interval between LDA and HDA cut-offs. Cut-off validation was conducted by assessing construct and discriminative ability in two cohorts including a total of 488 JDM patients. RESULTS: The calculated JDMAI1 cut-offs were ≤2.4 for ID, ≤6.6 for LDA, 6.7-11 for MDA and >11 for HDA. The calculated JDMAI2 cut-offs were ≤5.2 for ID, ≤8.5 for LDA, 8.6-11.3 for MDA and >11.3 for HDA. The cut-offs discriminated strongly among disease activity states defined subjectively by caring physicians and parents, parents' satisfaction or non-satisfaction with illness outcome, levels of pain, fatigue, physical functional impairment and physical well-being. CONCLUSIONS: Both JDMAI1 and JDMAI2 cut-offs revealed good metrologic properties in validation analyses and are, therefore, suited for application in clinical practice and research.
650    _2
$a dítě $7 D002648
650    _2
$a lidé $7 D006801
650    12
$a dermatomyozitida $x diagnóza $7 D003882
650    12
$a lékaři $7 D010820
650    12
$a revmatologie $7 D012219
650    _2
$a ROC křivka $7 D012372
650    _2
$a stupeň závažnosti nemoci $7 D012720
650    _2
$a randomizované kontrolované studie jako téma $7 D016032
655    _2
$a časopisecké články $7 D016428
700    1_
$a Consolaro, Alessandro $u UOC Reumatologia e Malattie Autoinfiammatorie, IRCCS Istituto Giannina Gaslini, Genova, Italy $u Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics and Maternal-Infantile Sciences (DiNOGMI), University of Genoa, Genova, Italy
700    1_
$a Pistorio, Angela $u Direzione Scientifica, IRCCS Istituto Giannina Gaslini, Genoa, Italy
700    1_
$a Rebollo-Giménez, Ana $u UOC Reumatologia e Malattie Autoinfiammatorie, IRCCS Istituto Giannina Gaslini, Genova, Italy
700    1_
$a Bracaglia, Claudia $u Division of Rheumatology, Ospedale Pediatrico Bambino Gesu, Rome, Italy $1 https://orcid.org/0000000298349619
700    1_
$a Dolezalova, Pavla $u 1st Faculty of Medicine, Charles University, General University Hospital in Prague, Prague, Czech Republic
700    1_
$a Guilaisne Bernard-Medina, Ana $u Servicio de Reumatología, Hospital Civil de Guadalajara Unidad Hospitalaria Fray Antonio Alcalde, Guadalajara, Mexico
700    1_
$a Herlin, Troels $u Pediatric Rheumatology Unit, Aarhus University Hospital, Aarhus, Denmark
700    1_
$a Trachana, Maria $u Thessaloniki University School of Medicine, First Department of Pediatrics, Pediatric Immunology and Rheumatology Referral Center, Hippokration General Hospital, Thessaloniki, Greece
700    1_
$a Vargová, Veronika $u Department of Paediatrics and Adolescent Medicine, Faculty of Medicine, Pavol Jozef Šafárik University in Košice, Kosice, Slovakia
700    1_
$a Wouters, Carine $u Pediatric Rheumatology and Immune-inflammatory diseases, and KU Leuven - University of Leuven, Department of Microbiology and Immunology, Laboratory Immunobiology, UZ Leuven - Universitair ziekenhuis, Leuven, Belgium
700    1_
$a Carenini, Laura $u UOC Servizio Sperimentazioni Cliniche Pediatriche, IRCCS Istituto Giannina Gaslini, Genoa, Italy
700    1_
$a Ruperto, Nicolino $u UOC Servizio Sperimentazioni Cliniche Pediatriche, IRCCS Istituto Giannina Gaslini, Genoa, Italy $1 https://orcid.org/0000000184077782
700    1_
$a Ravelli, Angelo $u Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics and Maternal-Infantile Sciences (DiNOGMI), University of Genoa, Genova, Italy $u Direzione Scientifica, IRCCS Istituto Giannina Gaslini, Genoa, Italy $1 https://orcid.org/0000000196580385
710    2_
$a Paediatric Rheumatology International Trials Organisation (PRINTO)
773    0_
$w MED00188812 $t RMD open $x 2056-5933 $g Roč. 10, č. 1 (2024)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38307698 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423155807 $b ABA008
999    __
$a ok $b bmc $g 2081293 $s 1216981
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 10 $c 1 $e 20240202 $i 2056-5933 $m RMD open $n RMD Open $x MED00188812
LZP    __
$a Pubmed-20240412

Find record

Citation metrics

Archiving options